U.S. markets open in 6 hours 22 minutes
  • S&P Futures

    3,848.75
    +39.50 (+1.04%)
     
  • Dow Futures

    31,176.00
    +264.00 (+0.85%)
     
  • Nasdaq Futures

    13,108.50
    +197.50 (+1.53%)
     
  • Russell 2000 Futures

    2,239.10
    +39.90 (+1.81%)
     
  • Crude Oil

    62.68
    +1.18 (+1.92%)
     
  • Gold

    1,752.00
    +23.20 (+1.34%)
     
  • Silver

    27.02
    +0.58 (+2.21%)
     
  • EUR/USD

    1.2074
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3958
    +0.0035 (+0.25%)
     
  • USD/JPY

    106.6440
    +0.1420 (+0.13%)
     
  • BTC-USD

    46,356.62
    +1,738.34 (+3.90%)
     
  • CMC Crypto 200

    926.46
    -6.68 (-0.72%)
     
  • FTSE 100

    6,483.43
    0.00 (0.00%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

What Kind Of Investors Own Most Of Forte Biosciences, Inc. (NASDAQ:FBRX)?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Forte Biosciences, Inc. (NASDAQ:FBRX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

With a market capitalization of US$437m, Forte Biosciences is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Forte Biosciences.

Check out our latest analysis for Forte Biosciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Forte Biosciences?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Forte Biosciences already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Forte Biosciences' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 29% of Forte Biosciences. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that ArrowMark Colorado Holdings, LLC is the largest shareholder with 23% of shares outstanding. Paul A. Wagner is the second largest shareholder owning 18% of common stock, and Franklin Resources, Inc. holds about 8.2% of the company stock. Paul A. Wagner, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Forte Biosciences

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

It seems insiders own a significant proportion of Forte Biosciences, Inc.. Insiders own US$99m worth of shares in the US$437m company. I would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, with a 22% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 2 warning signs for Forte Biosciences (1 makes us a bit uncomfortable!) that you should be aware of before investing here.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.